Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

T Chisesi

Showing results (71-80 of 89) with videos related to

Pageof 9
Sort By:
Haematologica|November 1, 1991
Mitoxantrone alone or in combination chemotherapy (VeMP) as second-line treatment in relapsed or refractory poor-prognosis non-Hodgkin's lymphoma. A report of the Non-Hodgkin's Lymphoma Co-operative Study Group (NHLCSG)G Santini, A Contu, A Porcellini, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 1, 1991
Autologous bone marrow transplantation for advanced stage adult lymphoblastic lymphoma in first complete remission. Report of the Non-Hodgkin's Lymphoma Cooperative Study Group (NHLCSG)G Santini, P Coser, T Chisesi, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 1, 1994
Long-term results of alpha interferon as initial therapy and splenectomy as consolidation therapy in patients with hairy cell leukemia. Final report from the Italian Cooperative Group for HCLM Federico, A Frassoldati, T Lamparelli, et al.
Leukemia & Lymphoma|July 28, 2016
Treatment of Early Stage Hodgkin's Disease According to Risk FactorsT Chisesi, M Vespignani, G Capnist, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 1, 1994
MACOP-B versus ProMACE-MOPP in the treatment of advanced diffuse non-Hodgkin's lymphoma: results of a prospective randomized trial by the non-Hodgkin's Lymphoma Cooperative Study GroupM R Sertoli, G Santini, T Chisesi, et al.
Cancer Detection and Prevention|January 1, 1988
Malignant lymphomas in patients with or at risk for AIDS: a report of 50 cases observed in ItalyS Monfardini, U Tirelli, E Vaccher, et al.
Clinical Immunology and Immunopathology|September 1, 1991
Clonally expanded CD3+, CD4-, CD8- cells bearing the alpha/beta or the gamma/delta T-cell receptor in patients with the lymphoproliferative disease of granular lymphocytesF Pandolfi, R Foa, G De Rossi, et al.
Thrombosis and Haemostasis|October 30, 1985
One year follow-up study of T-cell subsets and incidence of seropositivity for HTLV-I and HTLV-III antibodies in patients treated "on demand" or sporadically with clotting concentratesF Rodeghiero, G C Castaman, T Chisesi, et al.
Cancer|January 15, 1990
Clinical course and prognosis of the lymphoproliferative disease of granular lymphocytes. A multicenter studyF Pandolfi, T P Loughran, G Starkebaum, et al.
Leukemia & Lymphoma|May 9, 2001
Cemp, a mitoxantrone containing combination, in the treatment of intermediate and high grade non-hodgkin's lymphoma: an effective and non toxic therapeutic alternative for adult and elderly patientsT Chisesi, P Polistena, A Contu, et al.
Pageof 9

Showing results (71-80 of 89) with videos related to

Sort By:
Pageof 9
Haematologica|November 1, 1991
Mitoxantrone alone or in combination chemotherapy (VeMP) as second-line treatment in relapsed or refractory poor-prognosis non-Hodgkin's lymphoma. A report of the Non-Hodgkin's Lymphoma Co-operative Study Group (NHLCSG)G Santini, A Contu, A Porcellini, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 1, 1991
Autologous bone marrow transplantation for advanced stage adult lymphoblastic lymphoma in first complete remission. Report of the Non-Hodgkin's Lymphoma Cooperative Study Group (NHLCSG)G Santini, P Coser, T Chisesi, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 1, 1994
Long-term results of alpha interferon as initial therapy and splenectomy as consolidation therapy in patients with hairy cell leukemia. Final report from the Italian Cooperative Group for HCLM Federico, A Frassoldati, T Lamparelli, et al.
Leukemia & Lymphoma|July 28, 2016
Treatment of Early Stage Hodgkin's Disease According to Risk FactorsT Chisesi, M Vespignani, G Capnist, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 1, 1994
MACOP-B versus ProMACE-MOPP in the treatment of advanced diffuse non-Hodgkin's lymphoma: results of a prospective randomized trial by the non-Hodgkin's Lymphoma Cooperative Study GroupM R Sertoli, G Santini, T Chisesi, et al.
Cancer Detection and Prevention|January 1, 1988
Malignant lymphomas in patients with or at risk for AIDS: a report of 50 cases observed in ItalyS Monfardini, U Tirelli, E Vaccher, et al.
Clinical Immunology and Immunopathology|September 1, 1991
Clonally expanded CD3+, CD4-, CD8- cells bearing the alpha/beta or the gamma/delta T-cell receptor in patients with the lymphoproliferative disease of granular lymphocytesF Pandolfi, R Foa, G De Rossi, et al.
Thrombosis and Haemostasis|October 30, 1985
One year follow-up study of T-cell subsets and incidence of seropositivity for HTLV-I and HTLV-III antibodies in patients treated "on demand" or sporadically with clotting concentratesF Rodeghiero, G C Castaman, T Chisesi, et al.
Cancer|January 15, 1990
Clinical course and prognosis of the lymphoproliferative disease of granular lymphocytes. A multicenter studyF Pandolfi, T P Loughran, G Starkebaum, et al.
Leukemia & Lymphoma|May 9, 2001
Cemp, a mitoxantrone containing combination, in the treatment of intermediate and high grade non-hodgkin's lymphoma: an effective and non toxic therapeutic alternative for adult and elderly patientsT Chisesi, P Polistena, A Contu, et al.
Pageof 9